Regeneron Will Seek Approval For Eylea In DME This Year
This article was originally published in The Pink Sheet Daily
Executive Summary
Encouraging Phase III trial results will prompt the specialty pharma to submit its strong-selling ophthalmological entrant for another approval in diabetic macular edema. Regeneron already expects domestic sales of the drug to exceed $1 billion this year.